Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations

BACKGROUND: Mismatch repair deficiency (MMRD) is a common pathway of malignant transformation accounting for approximately 15–20 % of human carcinogensis. It has been postulated that MMRD increases tumor antigenicity and highlights a role for immunotherapeutic approach MMR-deficient cancers. This st...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro, Michael P., Goldstein, Neal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678532/
https://www.ncbi.nlm.nih.gov/pubmed/26674132
http://dx.doi.org/10.1186/s40425-015-0104-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678532/
https://www.ncbi.nlm.nih.gov/pubmed/26674132
http://dx.doi.org/10.1186/s40425-015-0104-y

Ejemplares similares